Sensitive and direct detection of circulating tumor cells by multimarker μ-nuclear magnetic resonance

Neoplasia (United States)

Volumn 14, Issue 5, 2012, Pages 388-395

  Ghazani, Arezou A ^a   Castro, Cesar M ^b   Gorbatov, Rostic ^a   Lee, Hakho ^a   Weissleder, Ralph ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; MUCIN 1; NANOPARTICLE; TETRAZINE DERIVATIVE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOPSY; CANCER DIAGNOSIS; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MICRO NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC;

EID: 84861657733     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1596/neo.12696     Document Type: Article

References (24)

1. van de Stolpe A, Pantel K, Sleijfer S, Terstappen LW, and den Toonder JM (2011). Circulating tumor cell isolation and diagnostics: toward routine clinical use. Cancer Res 71, 5955-5960.
2. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, et al. (2007). Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450, 1235-1239.
3. Pantel K, Brakenhoff RH, and Brandt B (2008). Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8, 329-340.
4. Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, Herold CI, Marcom PK, George DJ, and Garcia-Blanco MA (2011). Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res 9, 997-1007.
5. Cohen SJ, Punt CJA, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, et al. (2008). Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26, 3213-3221.
6. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, et al. (2004). Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351, 781-791.
7. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, and Raghavan D (2008). Circulating tumor cells predict survival benefit from treatment in metastatic castration resistant prostate cancer. Clin Cancer Res 14, 6302-6309.
8. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, Ward TH, Ferraldeschi R, Hughes A, Clack G, et al. (2011). Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 29, 1556-1563.
9. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW, et al. (2008). Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359, 366-377.
10. Giljohann DA and Mirkin CA (2009). Drivers of biodiagnostic development. Nature 462, 461-464.
11. Haun JB, Devaraj NK, Hilderbrand SA, Lee H, and Weissleder R (2010). Bioorthogonal chemistry amplifies nanoparticle binding and enhances the sensitivity of cell detection. Nat Nanotechnol 5, 660-665.
12. De Giorgi U, Valero V, Rohren E, Mego M, Doyle GV, Miller MC, Ueno NT, Handy BC, Reuben JM, Macapinlac HA, et al. (2010). Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol 21, 33-39.
13. Haun JB, Castro CM, Wang R, Peterson VM, Marinelli BS, Lee H, and Weissleder R (2011). Micro-NMR for rapid molecular analysis of human tumor samples. Sci Transl Med 3, 71ra16.
14. Issadore D, Min C, Liong M, Chung J, Weissleder R, and Lee H (2011). Miniature magnetic resonance system for point-of-care diagnostics. Lab Chip 11, 2282-2287.
15. Konigsberg R, Obermayr E, Bises G, Pfeiler G, Gneist M, Wrba F, de Santis M, Zeillinger R, Hudec M, and Dittrich C (2011). Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Acta Oncol 50, 700-710.
16. Mostert B, Kraan J, Bolt-de Vries J, van der Spoel P, Sieuwerts AM, Schutte M, Timmermans AM, Foekens R, Martens JW, Gratama JW, et al. (2011). Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146. Breast Cancer Res Treat 127, 33-41.
17. Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, Martens JW, Gratama JW, Sleijfer S, and Foekens JA (2009). Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 101, 61-66.
18. Sieuwerts AM, Mostert B, Bolt-de Vries J, Peeters D, de Jongh FE, Stouthard JM, Dirix LY, van Dam PA, Van Galen A, de Weerd V, et al. (2011). mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin Cancer Res 17, 3600-3618.
19. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, and Dirnhofer S (2004). Frequent EpCam protein expression in human carcinomas. Hum Pathol 35, 122-128.
20. Blick T, Widodo E, Hugo H, Waltham M, Lenburg ME, Neve RM, and Thompson EW (2008). Epithelial mesenchymal transition traits in human breast cancer cell lines. Clin Exp Metastasis 25, 629-642.
21. Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK, and Alpaugh RK (2011). Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 123, 19-26.
22. Poveda A, Kaye SB, McCormack R, Wang S, Parekh T, Ricci D, Lebedinsky CA, Tercero JC, Zintl P, and Monk BJ (2011). Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer. Gynecol Oncol 122, 567-572.
23. Meany DL and Chan DW (2011). Aberrant glycosylation associated with enzymes as cancer biomarkers. Clin Proteomics 8, 7.
24. Hanash SM, Baik CS, and Kallioniemi O (2011). Emerging molecular biomarkers- blood-based strategies to detect and monitor cancer. Nat Rev Clin Oncol 8, 142-150.